|
KIN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.01660951563099E-14 |
| Normal-vs-Stage2 |
2.412403610208E-11 |
| Normal-vs-Stage3 |
3.99680288865056E-15 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
1.359360E-01 |
| Stage1-vs-Stage3 |
1.197690E-02 |
| Stage1-vs-Stage4 |
3.56679999999887E-05 |
| Stage2-vs-Stage3 |
7.210400E-01 |
| Stage2-vs-Stage4 |
7.504100E-02 |
| Stage3-vs-Stage4 |
9.486000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
7.31069999981848E-07 |
| Normal-vs-Asian |
2.01590000248331E-08 |
| Caucasian-vs-AfricanAmerican |
6.637200E-01 |
| Caucasian-vs-Asian |
1.186810E-01 |
| AfricanAmerican-vs-Asian |
5.137200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.1094237467878E-15 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
3.985000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.66733293838206E-12 |
| Normal-vs-Age(41-60Yrs) |
1.55431223447522E-14 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.63602999999624E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.226000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.179880E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.452800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.821820E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.176800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.562000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.583140E-03 |
| Classical-VS-Follicular |
9.939200E-01 |
| Classical-VS-Other |
5.285200E-01 |
| Classical-VS-Normal |
1.62481139653892E-12 |
| Tall-VS-Follicular |
3.156800E-03 |
| Tall-VS-Other |
3.244200E-01 |
| Tall-VS-Normal |
2.01971772639808E-12 |
| Follicular-VS-Other |
6.127800E-01 |
| Follicular-VS-Normal |
1.53529999824542E-09 |
| Other-VS-Normal |
6.786400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.1094237467878E-15 |
| Normal-vs-N1 |
4.39579483924035E-11 |
| N0-vs-N1 |
5.483600E-01 |
|
|
